Key clinical point: Acalabrutinib has favorable efficacy versus standard of care for relapsed or refractory chronic lymphocytic leukemia.
Major finding: The estimated 18-month progression-free survival was 82% versus 48% with acalabrutinib versus standard of care.
Study details: Final results from the phase 3 ASCEND trial of 310 patients.
Disclosures: This study was sponsored by Acerta Pharma. Dr. Ghia reported consulting or advisory roles, grant or research funding, and/or honoraria from a variety of pharmaceutical companies.
Ghia P et al. SOHO 2020, Abstract CLL-091.